• 1. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 2. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Anisoles

Recent Advances in the Study of 1-(3-bromopropyl)-4-methoxybenzene (CAS: 57293-19-3) in Chemical Biology and Pharmaceutical Research

1-(3-bromopropyl)-4-methoxybenzene (CAS: 57293-19-3) is a brominated aromatic compound that has garnered significant attention in recent chemical biology and pharmaceutical research due to its versatile applications as a synthetic intermediate and potential bioactive molecule. This research brief synthesizes the latest findings on this compound, focusing on its synthetic utility, biological activities, and emerging applications in drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's role as a key building block in the synthesis of novel dopamine D2 receptor modulators. Researchers utilized 1-(3-bromopropyl)-4-methoxybenzene as a scaffold for introducing various pharmacophores, leading to the development of compounds with improved blood-brain barrier permeability compared to existing antipsychotic drugs. The bromopropyl moiety was particularly valuable for subsequent nucleophilic substitution reactions, enabling efficient structural diversification.

Recent advances in synthetic methodology have expanded the applications of 57293-19-3. A 2024 Nature Communications paper described a palladium-catalyzed cross-coupling protocol that allows direct functionalization of the benzene ring while preserving the reactive bromopropyl group. This breakthrough has enabled the parallel synthesis of diverse compound libraries for high-throughput screening against various biological targets.

In cancer research, derivatives of 1-(3-bromopropyl)-4-methoxybenzene have shown promising activity against histone deacetylases (HDACs). A 2023 study in Bioorganic & Medicinal Chemistry Letters reported that structural analogs bearing hydroxamic acid groups at the terminal position exhibited nanomolar inhibition against HDAC6, with improved selectivity profiles compared to current clinical inhibitors. Molecular modeling studies suggest the methoxybenzene moiety contributes significantly to binding pocket recognition.

The compound's pharmacokinetic properties have been systematically investigated in recent preclinical studies. Research published in European Journal of Pharmaceutical Sciences (2024) demonstrated that the bromopropyl chain length and methoxy substitution pattern significantly influence metabolic stability, with optimal derivatives showing extended half-lives in rodent models while maintaining favorable toxicity profiles.

Emerging applications include the use of 57293-19-3-derived probes for chemical biology studies. A 2024 ACS Chemical Biology report detailed the development of photoaffinity labeling agents based on this scaffold, enabling the identification of novel binding partners for G protein-coupled receptors. The bromine atom serves as an excellent handle for subsequent bioconjugation reactions in these applications.

Ongoing clinical translation efforts focus on optimizing the physicochemical properties of lead compounds derived from 1-(3-bromopropyl)-4-methoxybenzene. Recent patent filings (WO2023/189742) disclose crystalline forms with improved solubility and stability, addressing previous formulation challenges. These developments suggest this chemical scaffold will continue to play an important role in medicinal chemistry pipelines for neurological and oncological indications.

• 23464-42-8(Benzene, 1-(4-bromobutyl)-3-methoxy-)
• 35191-43-6(1-(4-bromobutyl)-4-methoxybenzene)
• 14469-84-2(1-Bromo-5-(4-methoxyphenyl)pentane)
• 123896-32-2(By 831-78 (9CI))
• 502760-11-4(Benzene, 1-(2-bromooctyl)-4-methoxy-)
• 105128-00-5(Benzene, 1-(3-bromopropyl)-3-phenoxy-)
• 38011-77-7(1-(3-Bromopropyl)-2-methoxybenzene)
• 16251-33-5(Benzene, 1-(3-bromopropyl)-4-phenoxy-)
• 874624-42-7(Naphthalene, 1-(3-bromopropyl)-6-methoxy-)
• 6943-97-1(1-(3-Bromopropyl)-3-methoxybenzene)